CriPec® nanomedicines: improved therapeutic performance
Cristal Therapeutics is a pharmaceutical company developing innovative nanomedicines based on proprietary polymeric technologies (CriPec®). Cristal Therapeutics’ mission is to improve the therapeutic performance of new and existing drugs, resulting in outstanding products in various therapeutic areas.
The application of CriPec® results in better efficacy and improved tolerability of drugs by improved disposition in the body and controlled exposure to the sites of action. The first product that is being developed by Cristal Therapeutics is CriPec® docetaxel for the treatment of solid tumours. Next to CriPec® docetaxel, the Cristal Therapeutics product portfolio comprises various early-stage products in various therapeutic areas.
Cristal Therapeutics develops these products independently, as well as in collaboration with other parties.